Perspective: repurposed drugs for COVID-19

Kesara Na-Bangchang; Supatra Porasuphatana; Juntra Karbwang

doi:10.5114/aoms/152467

Perspective: repurposed drugs for COVID-19

Arch Med Sci. 2022 Aug 30;18(5):1378-1391. doi: 10.5114/aoms/152467. eCollection 2022.

Authors

Kesara Na-Bangchang¹, Supatra Porasuphatana², Juntra Karbwang¹

Affiliations

¹ Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University, Pathumthani, Thailand.
² Department of Pharmacognosy and Toxicology, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand.

Abstract

Introduction: The article aims to emphasize the necessity of proper research design, both scientifically and ethically, in order to provide good evidence for physicians to base their decisions on when prescribing drug treatment.

Methods: Research articles and guidelines related to therapy of COVID-19 were searched from the PubMed database.

Results: Only remdesivir and tocilizumab are medicines that have been approved by the US FDA's decision to approve their clinical use in moderate and severe COVID-19.

Conclusions: Favipiravir, ivermectin and andrographolide need further well-conducted research to confirm the efficacy and safety against COVID-19 at different stages.

Keywords: COVID-19; andrographolide; azithromycin; favipiravir; ivermectin; remdesivir; tocilizumab.